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Immunological detection of secreted low molecular weight toxins represents a potentially novel means of diagnosing
infection by the fungus Aspergillus fumigatus. Two such metabolites, gliotoxin and helvolic acid, were selected and conjugated
to thyroglobulin for antisera generation in rabbits. Gliotoxin was initially activated using N-[ p-maleimidophenyl] isocyanate
(PMPI) and subsequently conjugated to S-acetyl thioglycolic acid N-hydroxysuccinimide-activated thyroglobulin, whereas
helvolic acid was activated with N-(3-Dimethylaminopropyl)-NV-ethylcarbodiimide (EDC) in the presence of thyroglobulin
prior to immunisation. To facilitate subsequent antisera evaluation, both toxins were similarly conjugated to bovine serum
albumin (BSA). Matrix-Assisted Laser Desorption Ionisation-Time Of Flight (MALDI-TOF) mass spectrometry and SDS-
PAGE analysis confirmed covalent attachment of toxins to BSA in the ratios of 15 and 2.4 mol per mol BSA for gliotoxin and
helvolic acid, respectively. Resultant high titer antisera were capable of detecting both BSA-conjugated toxins (inhibitory
concentration (IC)50: 4–5 Ag/ml). Free toxins were also detectable by competitive immunoassay, whereby 10 Ag/ml free
gliotoxin (30 AM) and helvolic acid (17 AM), respectively, inhibited antibody binding to cognate toxin–BSA previously
immobilised on microwells. This work confirms that sensitive and specific antisera can be raised against fungal toxins and may
have an application in diagnosing fungal infection.D 2003 Elsevier B.V. All rights reserved.Keywords: Gliotoxin; ELISA; MALDI-TOF; Hapten; Immunocompromised
1. Introduction serious form of aspergillosis, has a mortality rate ofThe filamentous fungus Aspergillus fumigatus is
responsible for a range of pulmonary infections in
immunocompromised patients and those with pre-
existing lung damage (Fraser, 1993; Daly and
Kavanagh, 2001). Invasive aspergillosis is the most0167-7012/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: sean.doyle@may.ie (S. Doyle).80–95% and occurs almost exclusively in individ-
uals with pre-existing lung damage or disease and
in those immunocompromised as a result of disease
or therapy (Denning, 1998). In this form of the
disease, there is invasion and necrosis of the lung
wall, in addition to whole body fungal dissemina-
tion, which results in the infection of a wide range
of organs (Daly and Kavanagh, 2001). Despite
aggressive anti-fungal chemotherapy, death usually
results 7–14 days post-diagnosis (Denning, 1996).
As part of its complement of virulence attributes A.
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dominantly the immunosuppressive gliotoxin (Ami-
tani et al., 1995a,b), and enzymes (proteases,
elastases, phospholipases) which hinder the host
immune response and facilitate tissue penetration,
respectively (Rinaldi, 1983). Furthermore, extracts
obtained from aspergillosis patient sputum have
been shown to damage human respiratory epithelial
cells (Amitani et al., 1995a). Subsequent analysis
confirmed that gliotoxin derived from clinical iso-
lates of A. fumigatus was the toxic agent and that
helvolic acid also caused complete ciliostasis and
epithelial cell disruption (Amitani et al., 1995b).
Current immunological tests to assess the presence
of aspergillosis primarily rely upon the detection of
Aspergillus antigens associated with the fungal cell
wall (mannans or galactomannans), however, sub-
optimal sensitivity and specificity have resulted in
limited clinical application (Meunier, 1996; Richard-
son and Kokki, 1998). Weig et al. (2001a,b) have
proposed the use of anti-mitogillin (Aspf1) antibody
as an alternative method for the detection of aspergil-
losis and, although controversial (Woo et al., 2001),
this method may prove to have a useful clinical
application. More recently, Woo et al. (2002) have
developed ELISA systems which detect A. fumigatus
galactomannan (Afmp1p) and anti-Afmp1p antibody
in invasive aspergillosis patients resulting in a com-
bined sensitivity of 86.7%. Although the application
of Aspergillus DNA detection systems has proven
useful in terms of correlation in fungal DNA reduction
with disease resolution and treatment efficacy, the
inability of nucleic acid-based systems to differentiate
between (i) fungal strains and (ii) colonisation and
infection remains problematical (Yeo and Wong,
2002).
Obviously, there is significant under-detection of
aspergillosis and in an effort to overcome this
problem, novel methods for the detection of glio-
toxin (e.g., RP-HPLC and in vitro cell-based sys-
tems which mimic the interaction of fungal hyphae
with human tissue) have been developed (Belka-
cemi et al., 1999; Daly and Kavanagh, 2002).
Although these systems have excellent potential
for confirmation of Aspergillus infection they are
not amenable to routine use in diagnostic laborato-
ries. Detection of specific fungal metabolites has
been discussed as an alternative to antibody, antigenor nucleic acid-based tests (Yeo and Wong, 2002).
Gliotoxin, a well-characterised fungal metabolite,
has potent immunosuppressive effects and is indic-
ative of invasive aspergillosis (Denning, 1998).
Similarly, Mitchell et al. (1997) have shown that
helvolic acid, produced by A. fumigatus, inhibits
the oxidative burst of macrophages. Consequently,
the appearance of these toxins may be indicative of
invasive aspergillosis since neither toxin has been
associated with infections caused by other clinically
relevant fungi. Thus, development of immunoas-
says, which could detect one or more toxins,
produced by the genus Aspergillus, would represent
a more reliable means of identifying underlying
fungal infection and facilitate an effective treatment
protocol. The aims of the work presented here were
to determine if antibodies could be produced
against fungal metabolites and to assess the func-
tionality of any resultant antibodies by enzyme
immunoassay.2. Materials and methods
2.1. Chemicals
All materials were purchased from Sigma-
Aldrich Chemical (Dorset, UK) unless otherwise
stated.
2.2. Preparation of helvolic acid–protein conjugates
Helvolic acid was prepared at 1 mg/ml in dimethyl
sulfoxide (DMSO). Briefly, 100 Al N-(3-Dimethyla-
minopropyl)-NV-ethylcarbodiimide (EDC; 10 mg/ml
in deionised water) was added to 25 Al of the toxin
to facilitate carboxyl group activation (Fig. 1), repre-
senting a 100-fold molar excess of EDC over toxin.
Immediately, 100 Al of either bovine serum albumin
(BSA) or thyroglobulin (10 mg/ml in 100 mM Meth-
anesulphonic acid, 500 mM NaCl pH 6.0) was added
to the helvolic acid/EDC mixture, agitated gently and
the reaction allowed to proceed for 2 h at room
temperature. This combination of reactants repre-
sented a 3- and 0.3-fold molar ratio of activated
helvolic acid to BSA and thyroglobulin, respectively.
Addition of hydroxylamine (10 mM final concentra-
tion) terminated the reaction. The resultant conjugates
Fig. 1. Structures of gliotoxin and helvolic acid used for conjugation
to thyroglobulin and bovine serum albumin (BSA), respectively.
Gliotoxin contains two hydroxyl groups available for activation
using N-[ p-maleimidophenyl] isocyanate (PMPI). Helvolic acid
contains a single carboxyl group which can be activated using N-(3-
Dimethylaminopropyl)-NV-ethylcarbodiimide (EDC) prior to protein
conjugation.
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stirring, at 4 jC against either phosphate buffered
saline (PBS) (prior to immunisation and subsequent
ELISA analysis) or deionised H2O prior to mass
spectrometry.
2.3. Preparation of gliotoxin–BSA conjugates
S-acetyl thioglycolic acid N-hydroxysuccinimide
(SATA; 1 mg/50 Al dimethylformamide (DMF))
was added to 10 ml of BSA (1 mg/ml in 50 mM
potassium phosphate, 150 mM NaCl, 1 mM EDTA
(Buffer A), pH 7.8). The solution was mixed
gently, allowed to incubate for 1 h and dialysed
extensively against Buffer A at pH 6.8. Thyroglob-
ulin was similarly activated with SATA. The extentof SATA incorporation was measured, and reactive
sulphydral groups exposed (deblocked), as previ-
ously described (Duncan et al., 1983). Gliotoxin (2
mg/ml in DMSO) was activated through available
hydroxyl groups (Fig. 1) by adding 50 to 105 Al N-
[ p-maleimidophenyl] isocyanate (PMPI; 30 mg/ml
in DMSO) (Annunziato et al., 1993) and brought to
a final volume of 310 Al with DMSO which
represented a 5-fold molar excess of PMPI over
gliotoxin. After reacting for 1 h at room tempera-
ture, PMPI-activated gliotoxin (260 Al) was added
to 2 ml deblocked SATA-BSA or SATA-thyroglob-
ulin (0.5 mg/ml in Buffer A pH 6.8). This combi-
nation of reactants represented a 20- and 2-fold
molar excess of activated gliotoxin to BSA and
thyroglobulin, respectively. After 2 h incubation,
conjugates were dialysed as described above (Sec-
tion 2.2). Both toxin–protein conjugates were ana-
lysed by SDS-PAGE, Western blotting and Matrix-
Assisted Laser Desorption Ionisation-Time Of Flight
(MALDI-TOF) mass spectrometry.
2.4. Polyclonal antibody generation
Four rabbits (New Zealand White female rabbits.
Age range: 6–12 months. Weight range: 3–4 kg.
Obtained from Harlan UK, Oxon, UK) were immu-
nised in total, two with each toxin–thyroglobulin
conjugate. Animals were initially immunised subcu-
taneously with 50 Ag of each thyroglobulin–toxin
conjugate in Freunds complete adjuvant (final vol-
ume = 3 ml (50:50 Freunds complete adjuvant: conju-
gate in PBS)). For subsequent immunisations (four, at
two-weekly intervals) 50 Ag of each thyroglobulin–
toxin conjugate in Freunds incomplete adjuvant
(50:50 with conjugate in PBS) was used until a
satisfactory titer (antigen detection (1 Ag) by Western
blot at greater than or equal to 1/2000 antisera
dilution) was achieved. Immunisations were carried
out according to Irish Department of Health Licence
B100/2622.
2.5. Protein–toxin conjugate analysis
Free and modified toxin–BSA conjugates were
evaluated by SDS-PAGE and Western blot analysis
(Ennis et al., 2001). Briefly, electrotransferred pro-
teins were detected using diluted immune antiserum
Fig. 2. (A) SDS-PAGE analysis of toxin–BSA conjugates (1 Ag/lane). Lane 1, molecular weight markers; Lane 2, BSA; Lane 3, helvolic acid–
BSA and Lane 4, gliotoxin–BSA. (B) Western blot analysis of toxin–BSA conjugates using rabbit antisera (1/2000). Immunoblotting was
carried out in two stages, whereby gliotoxin–BSA conjugate was initially detected when anti gliotoxin– thyroglobulin antisera was added to the
nitrocellulose membrane. Subsequent membrane incubation with anti helvolic acid– thyroglobulin antisera revealed the presence of helvolic
acid–BSA conjugate. Lane 1, BSA; Lane 2, Helvolic acid–BSA and Lane 3, gliotoxin–BSA. (C) MALDI-TOF mass spectrometry analysis of
BSA, gliotoxin–BSA and helvolic acid–BSA conjugates.
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Signal revelation was by goat IgG [anti-rabbit IgG]–
HRP conjugate and the Diaminobenzidine/H2O2 sub-
strate system. Mass spectrometry was carried out
using a Bruker Biflex 1V MALDI-TOF Mass Spec-
trometer. All samples were freeze-dried to 1 mg/ml,
deposited (1 Al) with 1 Al sinnipinic acid matrix onto a
mass spectrometry slide and allowed to dry prior to
analysis.
2.6. ELISA protocols
Toxin–BSA conjugates were individually diluted
in 200 mM sodium carbonate pH 9.6. Flat-bottomed
microtiter plates (MaxiSorpk Nunc-Immunok Mod-Fig. 3. Determination of antisera reactivity against toxin–BSA conjugate
toxin– thyroglobulin conjugate. (A) Antisera reactivity against immobilis
against immobilised helvolic acid–BSA (02-3H and 02-4H). Gliotox
immobilised gliotoxin BSA. Helvolic acid– thyroglobulin antisera did not
out in all cases.ules; Nalge NUNC International, Roskilde, Denmark)
were subsequently coated at 37 jC for 1 h with
saturating amounts of helvolic acid–BSA conjugates
(1 Ag/ml; 100 Al/well). Optimal gliotoxin–BSA coat-
ing was found to be 5 Ag/ml (100 Al/well). After
coating, microtiter plates were washed twice with
phosphate buffered saline–0.05%(v/v) Tween-20
(PBST) followed by addition of blocking solution
(1%(w/v) BSA in coating buffer; 200 Al/well) to
stabilise bound toxin–protein conjugates and mini-
mise non-specific binding. Immune antisera, diluted
from 1/5000–1/40000 in PBST, was added without
the relevant toxin (final volume: 100 Al/well). In the
case of competitive ELISA formats for both toxins,
microplate coating at 5 Ag/ml was used for gliotoxin 
s by ELISA. Four rabbits were immunised in total, two with each
ed gliotoxin–BSA (02-5G and 02-6G) and (B) antisera reactivity
in– thyroglobulin antisera reveals relatively high specificity for
bind to immobilised gliotoxin–BSA. Duplicate analysis was carried
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ly. In addition, relevant antisera and toxin were either
added immediately or pre-incubated for 1 or 16 h prior
to addition to the microtiter plate. The free toxin
concentration range was 0–50 Ag/ml. Following incu-
bation (1 h), the plate was washed four times with
PBST and goat IgG [anti-rabbit IgG]–HRP conjugate
added (100 Al/well; 1/1000 in Buffer B) for 1 h. The
plate was washed four times and tetramethylbenzidine
substrate (BioFX Laboratories, MD, USA) was added
for 10 min. The reaction was stopped by adding 1 N
H2SO4 and the absorbance was read at 450/630 nm
using an MRX microtitre plate reader (Dynex Tech-
nologies, West Sussex, UK).Fig. 4. Inhibition profiles for toxin– thyroglobulin antisera binding
to immobilised toxin–BSA following co-incubation with cognate
toxin–BSA conjugate (-y-) free BSA (-n-) or thyroglobulin (-E-).
IC50 values ranged from 4 to 5 Ag/ml. Duplicate analysis was
carried out in all cases.3. Results
3.1. Toxin–protein conjugate formation
Toxin–protein conjugates were synthesised (i) to
enhance the immune response against the toxin moi-
eties and (ii) to facilitate toxin immobilisation on
microplates for enzyme immunoassay. Gliotoxin- and
helvolic acid–BSA conjugates were each analysed by
SDS-PAGE, Western blot and MALDI-TOF mass
spectrometry (Fig. 2A–C). Western blot analysis
(Fig. 2B) was carried out in two stages and only
gliotoxin–BSA conjugate (lane 3, Fig. 2B) was
detected when anti gliotoxin–thyroglobulin antisera
was added to the nitrocellulose membrane and
detected as described in Section 2.5. Subsequent
membrane incubation with anti helvolic acid–thyro-
globulin antisera revealed the presence of helvolic
acid–BSA conjugate. Unconjugated BSA was not
detected by any antiserum used and high molecular
weight conjugate formation is evident in Fig. 2B (lanes
2–3), possibly as a result of protein cross-linking.
SDS-PAGE and Western blot analysis of gliotoxin–
BSA (Fig. 2A (lane 4) and B) resulted in the detection
of a band at an apparent Mr of 78 kDa, which confirms
a loading of 15 mol gliotoxin/mol BSA. Interestingly,
MALDI-TOF analysis of gliotoxin–BSA indicates a
hapten loading of only 4 mol gliotoxin/mol BSA (Fig.
2C) (see Discussion). Although SDS-PAGE did not
exhibit sufficient resolution to detect bound helvolic
acid, MALDI-TOF analysis for the helvolic acid–BSA
conjugate confirmed a hapten loading of 2.4 molhelvolic acid/mol BSA. Due to the relatively large
size, thyroglobulin conjugates could not be analysed
by mass spectrometry and the degree of hapten loading
could not be determined by SDS-PAGE due to limi-
tations in resolution and the large protein size relative
to that of the haptenylated form.
3.2. Anti-toxin antisera titer and specificity evaluation
by ELISA
Resultant antibody titers and specificity for all
both immunogens is shown in Fig. 3. Fig. 3A
illustrates the reactivity of antisera raised against
gliotoxin- and helvolic acid–thyroglobulin conju-
gates, respectively, against immobilised gliotoxin–
BSA over a range of antisera dilutions ranging
from 1/5000 to 1/40000. Specific detection of
immobilised gliotoxin–BSA is evident at an anti-
serum (anti gliotoxin–thyroglobulin) dilution of 1/
40000 which was in turn selected as the optimal
antiserum dilution for the detection of free glio-
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dilutions of helvolic acid–thyroglobulin antisera,
minimal cross-reactivity with bound conjugate is
detected at antisera levels greater than 1/10000
dilution.
The reactivity of antisera against immobilised
helvolic acid–BSA conjugate is shown in Fig. 3B.
Significantly, gliotoxin–thyroglobulin antisera doesFig. 5. (A) Inhibition of gliotoxin– thyroglobulin antisera (1/40000) bindin
5 Ag/ml) by free gliotoxin. Antisera and free gliotoxin were either added imm
prior to addition to coated microwells. (B) Inhibition (41%) of gliotoxin– thy
(microwell coating concentration: 1 Ag/ml) by free gliotoxin. Antisera and
(C) Inhibition of helvolic acid– thyroglobulin antisera (1/2000 (-E-), 1/8000
(microwell coating concentration: 0.05 Ag/ml) by free helvolic acid. Antisera
pre-incubation was necessary. Duplicate analysis was carried out in all casnot bind to helvolic acid–BSA antigen at any dilution
tested. In all cases, pre-immune antisera did not detect
either immobilised gliotoxin- or helvolic acid–BSA
conjugates. Furthermore, immune antisera did not
bind to unmodified BSA immobilised at the same
coating concentration as toxin–BSA conjugates,
thereby confirming the specificity of the respective
antisera for the conjugated toxin moieties.g to immobilised gliotoxin–BSA (microwell coating concentration:
ediately to microwells (-E-) or incubated for 1 h (-n-) or 16 h (-y-)
roglobulin antisera (1/5000) binding to immobilised gliotoxin–BSA
free gliotoxin were added immediately to microwells after mixing.
(-n-) or 1/32000 (-y-)) binding to immobilised helvolic acid–BSA
and free helvolic acid were added immediately to microwells and no
es.
iological Methods 56 (2004) 221–2303.3. Toxin–protein conjugate inhibition of antibody
binding
Further evaluation of toxin–protein antisera was
performed by determining the extent of inhibition of
antisera binding due to the presence of either the
appropriate toxin–BSA conjugate or free BSA. It is
clear from Fig. 4 that free BSA (or thyroglobulin)
does not interfere with antibody binding to the re-
spective immobilised toxin conjugate. However, the
addition of free toxin–BSA to gliotoxin- and helvolic
acid–thyroglobulin antisera, respectively, at dilutions
of 1/40000 and 1/16000, completely inhibits antibody
binding to the immobilised toxins with inhibitory
concentration (IC)50 values ranging from 4 to 5 Ag/
ml in all cases.
3.4. Inhibition of toxin– thyroglobulin antiserum
binding by free toxin
Free gliotoxin inhibits antiserum (anti gliotoxin–
thyroglobulin) binding to immobilised gliotoxin–
BSA conjugate in a time- and concentration-depen-
dent manner. Fig. 5A shows standard curves obtained
following data normalisation by B/Bo transformation
(Davies, 1994) prior to plotting against free gliotoxin
concentration between 0 and 50 Ag/ml. The standard
curves represent the results obtained following glio-
toxin pre-incubation with antiserum (gliotoxin–thyro-
globulin) for 0, 1 and 16 h incubation prior to addition
to microwells pre-coated with gliotoxin–BSA and the
assay then performed as per Section 2.6. The greater
degree of inhibition obtained following 16 h incuba-
tion of free gliotoxin with cognate antiserum suggests
that relevant IgG exhibits low avidity for free glio-
toxin. Microplate coating at 1 Ag/ml gliotoxin–BSA
and reduction in antiserum dilution to 1/5000 (from 1/
40000) facilitated a 41% reduction in antibody bind-
ing at 50 Ag/ml gliotoxin (Fig. 5B). Apart from this,
alteration in assay conditions through the use of
alternative buffers/pH has not resulted in a significant
improvement in assay performance. Neither has the
addition of low concentrations of reducing agents
such as dithiothreitol, which confirms that antibody
reactivity is most likely not directed against the
reduced form of gliotoxin. Fig. 5C shows a standard
curve for free helvolic acid detection by competitive
enzyme immunoassay as a result of the inhibition of
M. Fox et al. / Journal of Microb228helvolic acid– thyroglobulin antiserum binding to
immobilised helvolic acid–BSA conjugate by free
helvolic acid in a concentration-dependent manner.
Interestingly, the time-dependent inhibition of antise-
rum binding to immobilised helvolic acid–BSA was
not as significant as that observed for gliotoxin (data
not shown). Thus, in both cases, antibodies raised
against thyroglobulin–toxin conjugates were capable
of recognising the free toxins in competitive enzyme
immunoassay formats.4. Discussion
Conventional assays for the detection of Aspergil-
lus infection rely upon the identification of cell wall
components released by the fungus during infection.
While these antibody-based assays have a number of
applications they can yield false positives and may
also fail to detect infection where shedding of cell
wall material has not occurred (Yeo and Wong, 2002).
A number of protein or non-proteinaceous toxins
produced by A. fumigatus play a crucial role in
assisting the fungus to colonise and penetrate pulmo-
nary tissue and may be detected in blood, urine or
sputum specimens (Amitani et al., 1995a; Daly and
Kavanagh, 2001). As a consequence, we have sought
to develop a series of antibody-based immunoassays
to detect fungal toxins previously implicated in tissue
invasion since these could represent an improved
means of identifying Aspergillosis.
The work presented here contains the first descrip-
tion of the preparation of thyroglobulin-based immu-
nogens for the fungal toxins, gliotoxin and helvolic
acid. We further describe the generation of sensitive
and specific polyclonal antibodies, which are capable
of detecting both protein-coupled, and free toxins, and
finally the development of microplate-based, compet-
itive immunoassay formats to detect both toxins.
Thyroglobulin was chosen as the carrier protein for
immunisation as theoretically it should contain a
greater number of amino groups available for hapten
coupling relative to BSA (Hermanson, 1996). Al-
though toxin–thyroglobulin conjugates could not be
readily characterised prior to immunisation, due to
their large size (>660 kDa), the approach of simulta-
neous synthesis and characterisation of toxin–BSA
conjugates by SDS-PAGE and MALDI-TOF mass
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and PMPI/SATA) employed for protein modification
were successful. Indeed, the subsequent analysis of all
antisera generated confirmed the validity of this
strategy.
High molecular weight conjugate formation was
evident following Western blot analysis of both tox-
in–BSA conjugates (Fig. 2B). This is most likely due
to antibody reactivity against toxin modified/EDC
cross-linked BSA which was also formed during
toxin–protein coupling. It is possible that similar high
molecular weight conjugates were formed during
toxin–thyroglobulin synthesis and may have contrib-
uted to the significant immunogenicity of resultant
conjugates. Using MALDI-TOF mass spectrometry,
Keough et al. (1997) have shown the maximum
hapten loading of human serum albumin (HSA) to
be 17.9 mol phthalic anhydride/mol HSA. The values
for hapten coupling to BSA in the present work are
somewhat lower, and possibly result from the differ-
ential reactivity of q-amino groups in BSA towards
activated fungal toxins relative to those in HSA.
Interestingly, addition of sulpho-N-hydroxy succini-
mide to the EDC-mediated coupling reaction did not
enhance conjugate formation (data not shown).
A discrepancy arose with respect to gliotoxin
loading on BSA, whereby SDS-PAGE confirmed a
loading of 15 mol gliotoxin/mol BSA while MALDI-
TOF mass spectrometry indicated only 4 mol glio-
toxin/mol BSA. Previous analysis of gliotoxin has
suggested that the molecule fragments when mass
spectrometry is used as a means of detection (Taylor
et al., 1996), thus it is likely that gliotoxin has been
cleaved or degraded from BSA conjugates resulting in
the appearance of an incorrect conjugate m/z ratio by
mass spectrometry. Thus, we believe the estimate of
15 mol gliotoxin/mol BSA by SDS-PAGE is a more
reliable estimate of hapten loading.
Initial screening of anti toxin–thyroglobulin anti-
sera by Western blotting was supplemented by rigor-
ous microplate enzyme immunoassay evaluation of
antisera titer and specificity. Data presented in Figs. 3
and 4 confirm the specificity of two preparations of
anti gliotoxin–thyroglobulin antisera (02-5G and 02-
6G). It is clear that antiserum 02-5G had a higher titer
(Fig. 3) and was unreactive against immobilised
helvolic acid–BSA conjugates. It was therefore used
for gliotoxin detection by competitive immunoassay.Furthermore, only gliotoxin–BSA, and neither free
BSA nor thyroglobulin, was capable of inhibiting
cognate antiserum binding to immobilised glio-
toxin–BSA (Fig. 4). The IC50 values (Fig. 4) obtained
for both toxin–protein conjugates (4–5 Ag/ml) equa-
tes to approximately 70 nM toxin–protein and indi-
cates the relatively high affinity each antiserum
preparation for protein coupled toxin.
Work by Chan and Ho (2002) has recently dem-
onstrated the utility of protein-conjugated haptens in
eliciting anti hapten–protein polyclonal antibodies.
Here, we demonstrate that such antibodies can be
further utilised to detect free, in addition to, conjugat-
ed haptens. A minimum of 15–30 AM gliotoxin (5–
10 Ag/ml) was detectable by competitive immunoas-
say following overnight incubation of free toxin with
anti gliotoxin–thyroglobulin antiserum. This is com-
parable to the lower limit of sensitivity (10 AM)
recently reported by Tuomola et al. (2000) for the
detection of 3-methylindole using anti-3-methylindole
monoclonal antibodies and high sensitivity fluoromet-
ric detection. It can be seen from Fig. 5B that a 5
reduction in gliotoxin–BSA coating level (to 1 Ag/ml)
facilitated the detection of free gliotoxin, whereby a
41% decrease in anti gliotoxin–thyroglobulin binding
to immobilised gliotoxin–BSA was evident in the
absence of any pre-incubation with free toxin. Initial
attempts to detect free toxins using microplates coated
at saturating concentrations of helvolic–BSA conju-
gate were unsuccessful (data not shown). Consequent-
ly, it was decided to coat microplates at lower coating
concentrations of the toxin–BSA conjugate with the
intent to enhance the likelihood of antibody reactivity
with free as opposed to immobilised toxin. This
strategy proved successful. With respect to helvolic
acid, no pre-incubation with respective antiserum was
required to enable the detection of free helvolic acid
on microplates pre-coated at 0.05 Ag/ml helvolic–
BSA conjugate (Fig. 5C). Again, a sensitivity of
detection equivalent to 17 AM helvolic acid (10 Ag/
ml) was achieved.
In summary, hapten conjugate synthesis has fa-
cilitated the development of competitive immunoas-
say formats for the detection of the fungal toxins,
gliotoxin and helvolic acid. Work directed towards
the generation of monoclonal antibodies against
these molecules, in addition to the assessment of
the resultant diagnostic potential, is currently under-
M. Fox et al. / Journal of Microbiological Methods 56 (2004) 221–230230way. The ability to detect toxins secreted by Asper-
gillus in vivo may facilitate the rapid diagnosis of
aspergillosis and result in improved treatment and
recovery.Acknowledgements
This work was funded by Enterprise Ireland
Strategic Research Grant (ST/00/0078A) and, in part,
by the Higher Education Authority—Programme for
Research in Third Level Institutions (PRTLI): Cycle 3.References
Amitani, R., Murayama, T., Nawada, R., Lee, W.J., Niimi, A.,
Suzuki, K., Tanaka, E., Kuze, F., 1995a. Aspergillus culture
filtrates and sputum sols from patients with pulmonary asper-
gillosis cause damage to human respiratory ciliated epithelium
in vitro. Eur. Respir. J. 8, 1681.
Amitani, R., Taylor, G., Eleziz, E., Jones, C.L., Mitchell, J., Kuze,
F., Cole, P.J., Wilson, R., 1995b. Purification and character-
isation of factors produced by Aspergillus fumigatus which
affect human ciliated respiratory epithelium. Infect. Immun. 63,
3266.
Annunziato, M.E., Patel, U.S., Ranade, M., Palumbo, P.S., 1993. p-
Maleimidophenyl isocyanate: a novel heterobifunctional linker
for hydroxyl to thiol coupling. Bioconjug. Chem. 4 (3), 212.
Belkacemi, L., Barton, R.C., Hopwood, V., Evans, E.G., 1999.
Determination of optimum growth conditions for gliotoxin pro-
duction by Aspergillus fumigatus and development of a novel
method for gliotoxin detection. Med. Mycol. 37 (4), 227.
Chan, E.C., Ho, P.C., 2002. Preparation and characterization of
immunogens for antibody production against metanephrine
and normetanephrine. J. Immunol. Methods 266 (1–2), 143.
Daly, P., Kavanagh, K., 2001. Pulmonary Aspergillosis: clinical
presentation, diagnosis and therapy. Br. J. Biomed. Sci. 58, 197.
Daly, P., Kavanagh, K., 2002. Immobilisation of Aspergillus fumi-
gatus colonies in a soft agar matrix allows visualisation of A549
cell detachment and death. Med. Mycol. 40, 27.
Davies, C., 1994. In: Wild, D. (Ed.), The Immunoassay Handbook.
Stockton Press, NY, USA, pp. 8–38.
Denning, D.W., 1996. Aspergillosis: diagnosis and treatment. Int. J.
Antimicrob. Agents 6, 161.
Denning, D.W., 1998. Invasive aspergillosis. Clin. Infect. Dis. 26,
781.
Duncan, R.J., Weston, P.D., Wrigglesworth, R., 1983. A new re-agent which may be used to introduce sulfhydryl groups into
proteins, and its use in the preparation of conjugates for immu-
noassay. Anal. Biochem. 132 (1), 68.
Ennis, O., Corcoran, A., Kavanagh, K., Mahon, B.P., Doyle, S.,
2001. Baculovirus expression of parvovirus B19 (B19V) NS1:
utility in confirming recent infection. J. Clin. Virol. 22, 55.
Fraser, R.S., 1993. Pulmonary aspergillosis: pathologic and patho-
genetic features. Pathol. Annu. 28, 231.
Hermanson, G.T., 1996. Bioconjugate Techniques. Academic Press,
San Diego, CA, USA.
Keough, T., Lacey, M.P., Trakshel, G.M., Asquith, T.N., 1997. The
use of MALDI mass spectrometry to characterise synthetic pro-
tein conjugates. Int. J. Mass Spectrom. Ion Process. 169/170,
201.
Meunier, F., 1996. Current clinical issues on mycoses in neutro-
penic patients. Int. J. Antimicrob. Agents 6, 135.
Mitchell, C.G., Slight, J., Donaldson, K., 1997. Diffusible compo-
nent from the spore surface of the fungus Aspergillus fumigatus
which inhibits the macrophage oxidative burst is distinct from
gliotoxin and other hyphal toxins. Thorax 52 (9), 796.
Richardson, M.D., Kokki, M.H., 1998. Diagnosis and prevention of
fungal infection in the immunocompromized patient. Blood
Rev. 12, 241.
Rinaldi, M.G., 1983. Invasive aspergillosis. Rev. Infect. Dis. 5,
1061.
Taylor, G.W., Donnelly, L.E., Murray, S., Rendell, N.B., 1996.
Excursions in biomedical mass spectrometry. Br. J. Clin. Phar-
macol. 42 (1), 119.
Tuomola, M., Harpio, R., Mikola, H., Knuuttila, P., Lindstrom, M.,
Mukkala, V.M., Matikainen, M.T., Lovgren, T., 2000. Produc-
tion and characterisation of monoclonal antibodies against a
very small hapten, 3-methylindole. J. Immunol. Methods 240
(1–2), 111.
Weig, M., Frosch, M., Tintelnot, K., Haas, A., Linsmeier, B., Hee-
seman, J., 2001a. Use of recombinant mitogillin for improved
serodiagnosis of Aspergillus fumigatus-associated diseases. J.
Clin. Microbiol. 39 (5), 1721.
Weig, M., Gross, U., Domhof, S., Brunner, E., 2001b. Use of
recombinant mitogillin for serodiagnosis of Aspergillus fumiga-
tus-associated diseases. J. Clin. Microbiol. 39 (12), 4598.
Woo, P.C., Leung, A.S., Lau, S.K., Chong, K.T., Yuen, K.Y., 2001.
Use of recombinant mitogillin for serodiagnosis of Aspergillus
fumigatus-associated diseases. J. Clin. Microbiol. 39 (12), 4598.
Woo, P.C., Chan, C.M., Leung, A.S., Lau, S.K., Che, X.Y., Wong,
S.S., Cao, L., Yuen, K.Y., 2002. Detection of cell wall galacto-
mannoprotein Afmp1p in culture supernatants of Aspergillus
fumigatus and in sera of aspergillosis patients. J. Clin. Micro-
biol. 40 (11), 4382.
Yeo, S.F., Wong, B., 2002. Current status of nonculture methods for
diagnosis of invasive fungal infections. Clin. Microbiol. Rev.
15, 465.
